Source: Four out of five national US plan payers and nine of 16 regional payers said they were very concerned about the financial risk associated with gene therapies , according to a survey by the National Pharmaceutical Council and Analysis Group . It also found all national and 50 % of regional plans would consider at least one alternative payment method for gene therapy treatment in the next three years . Almost all said this would be dependent on evidence - based requirements , while 95 % said non - response to a treatment would be a ' deal off ' .
Four out of five national US plan payers and nine of 16 regional payers said they were very concerned about the financial risk associated with gene therapies , according to a survey by the National Pharmaceutical Council and Analysis Group . It also found all national and 50 % of regional plans would consider at least one alternative payment method for gene therapy treatment in the next three years . Almost all said this would be dependent on evidence - based requirements , while 95 % said non - response to a treatment would be a ' deal off ' .